Davis's Drug Guide
tremelimumab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
tre-me-lim-ue-mab
Trade Name(s)
- Imjudo
Ther. Class.
Pharm. Class.
monoclonal antibodies
cytotoxic t lymphocyte antigen 4 inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Tremelimumab." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580102/all/tremelimumab.
Vallerand AHA, Sanoski CAC. Tremelimumab. Davis's Drug Guide. F.A. Davis Company; 2026. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580102/all/tremelimumab. Accessed June 26, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Tremelimumab. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580102/all/tremelimumab
Vallerand AHA, Sanoski CAC. Tremelimumab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 June 26]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580102/all/tremelimumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - tremelimumab
ID - 3580102
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580102/all/tremelimumab
PB - F.A. Davis Company
ET - 20
DB - Medicine Central
DP - Unbound Medicine
ER -
